Skip to main content
. 2022 Aug;63(8):1145–1148. doi: 10.2967/jnumed.121.262940

FIGURE 3.

FIGURE 3.

Relationship between patient best response to T-DM1 and measured tumor uptake of 64Cu-DOTA-trastuzumab. Dashed lines show optimal thresholds relating response to uptake for individual tumors (day 1, 4.6 g/mL; day 2, 5.5 g/mL). Group mean SUVmax (responsive vs. nonresponsive patients) was significantly different (t test) for day 2 average (8.5 vs. 5.4, P < 0.05), day 1 minimum (5.6 vs. 2.8, P < 0.02), and day 2 minimum (8.1 vs. 3.2, P < 0.01). (P = 0.08 for day 1 average). *Fisher exact test for response vs. threshold.